190 related articles for article (PubMed ID: 35068399)
41. A systematic review on understanding the mechanistic pathways and clinical aspects of natural CDK inhibitors on cancer progression.: Unlocking cellular and biochemical mechanisms.
Asghar A; Chohan TA; Khurshid U; Saleem H; Mustafa MW; Khursheed A; Alafnan A; Batul R; Bin Break MK; Almansour K; Anwar S
Chem Biol Interact; 2024 Apr; 393():110940. PubMed ID: 38467339
[TBL] [Abstract][Full Text] [Related]
42. Cancer therapy: targeting cell cycle regulators.
Johansson M; Persson JL
Anticancer Agents Med Chem; 2008 Oct; 8(7):723-31. PubMed ID: 18855574
[TBL] [Abstract][Full Text] [Related]
43. Cyclin-dependent kinase inhibitors for the treatment of chronic lymphocytic leukemia.
Blachly JS; Byrd JC; Grever M
Semin Oncol; 2016 Apr; 43(2):265-73. PubMed ID: 27040705
[TBL] [Abstract][Full Text] [Related]
44. Small Molecule CDK Inhibitors for the Therapeutic Management of Cancer.
Goel B; Tripathi N; Bhardwaj N; Jain SK
Curr Top Med Chem; 2020; 20(17):1535-1563. PubMed ID: 32416692
[TBL] [Abstract][Full Text] [Related]
45. An Overview of CDK Enzyme Inhibitors in Cancer Therapy.
Mounika P; Gurupadayya B; Kumar HY; Namitha B
Curr Cancer Drug Targets; 2023; 23(8):603-619. PubMed ID: 36959160
[TBL] [Abstract][Full Text] [Related]
46. Cyclin dependent kinases in cancer: potential for therapeutic intervention.
Canavese M; Santo L; Raje N
Cancer Biol Ther; 2012 May; 13(7):451-7. PubMed ID: 22361734
[TBL] [Abstract][Full Text] [Related]
47. The anticancer activity of the substituted pyridone-annelated isoindigo (5'-Cl) involves G0/G1 cell cycle arrest and inactivation of CDKs in the promyelocytic leukemia cell line HL-60.
Saleh AM; Aljada A; El-Abadelah MM; Taha MO; Sabri SS; Zahra JA; Aziz MA
Cell Physiol Biochem; 2015; 35(5):1943-57. PubMed ID: 25870953
[TBL] [Abstract][Full Text] [Related]
48. Fadraciclib (CYC065), a novel CDK inhibitor, targets key pro-survival and oncogenic pathways in cancer.
Frame S; Saladino C; MacKay C; Atrash B; Sheldrake P; McDonald E; Clarke PA; Workman P; Blake D; Zheleva D
PLoS One; 2020; 15(7):e0234103. PubMed ID: 32645016
[TBL] [Abstract][Full Text] [Related]
49. Activation of cdk4 and cdk2 during rat liver regeneration is associated with intranuclear rearrangements of cyclin-cdk complexes.
Jaumot M; Estanyol JM; Serratosa J; Agell N; Bachs O
Hepatology; 1999 Feb; 29(2):385-95. PubMed ID: 9918914
[TBL] [Abstract][Full Text] [Related]
50. Targeting Cyclin-Dependent Kinases and Cell Cycle Progression in Human Cancers.
Santo L; Siu KT; Raje N
Semin Oncol; 2015 Dec; 42(6):788-800. PubMed ID: 26615126
[TBL] [Abstract][Full Text] [Related]
51. Novel CDKs inhibitors for the treatment of solid tumour by simultaneously regulating the cell cycle and transcription control.
Wang X; Deng K; Wang C; Li Y; Wang T; Huang Z; Ma Y; Sun P; Shi Y; Yang S; Fan Y; Xiang R
J Enzyme Inhib Med Chem; 2020 Dec; 35(1):414-423. PubMed ID: 31899991
[TBL] [Abstract][Full Text] [Related]
52. Antitumor activity of UCN-01 in carcinomas of the head and neck is associated with altered expression of cyclin D3 and p27(KIP1).
Patel V; Lahusen T; Leethanakul C; Igishi T; Kremer M; Quintanilla-Martinez L; Ensley JF; Sausville EA; Gutkind JS; Senderowicz AM
Clin Cancer Res; 2002 Nov; 8(11):3549-60. PubMed ID: 12429646
[TBL] [Abstract][Full Text] [Related]
53. P276-00, a novel cyclin-dependent inhibitor induces G1-G2 arrest, shows antitumor activity on cisplatin-resistant cells and significant in vivo efficacy in tumor models.
Joshi KS; Rathos MJ; Mahajan P; Wagh V; Shenoy S; Bhatia D; Chile S; Sivakumar M; Maier A; Fiebig HH; Sharma S
Mol Cancer Ther; 2007 Mar; 6(3):926-34. PubMed ID: 17363487
[TBL] [Abstract][Full Text] [Related]
54. Expression of cyclins and cdks throughout murine carcinogenesis.
Yerly-Motta V; Contassot E; Pavy JJ; Tiberghien P; Hervé P
Cell Mol Biol (Noisy-le-grand); 1999 Dec; 45(8):1217-28. PubMed ID: 10643971
[TBL] [Abstract][Full Text] [Related]
55. Efficacy of the combination of MEK and CDK4/6 inhibitors in vitro and in vivo in KRAS mutant colorectal cancer models.
Lee MS; Helms TL; Feng N; Gay J; Chang QE; Tian F; Wu JY; Toniatti C; Heffernan TP; Powis G; Kwong LN; Kopetz S
Oncotarget; 2016 Jun; 7(26):39595-39608. PubMed ID: 27167191
[TBL] [Abstract][Full Text] [Related]
56. Characterization of the interactions between human cdc25C, cdks, cyclins and cdk-cyclin complexes.
Morris MC; Divita G
J Mol Biol; 1999 Feb; 286(2):475-87. PubMed ID: 9973565
[TBL] [Abstract][Full Text] [Related]
57. Ginsenoside Rh2-mediated G1 phase cell cycle arrest in human breast cancer cells is caused by p15 Ink4B and p27 Kip1-dependent inhibition of cyclin-dependent kinases.
Choi S; Kim TW; Singh SV
Pharm Res; 2009 Oct; 26(10):2280-8. PubMed ID: 19629651
[TBL] [Abstract][Full Text] [Related]
58. Chemosensitization of HT29 and HT29-5FU Cell Lines by a Combination of a Multi-Tyrosine Kinase Inhibitor and 5FU Downregulates ABCC1 and Inhibits PIK3CA in Light of Their Importance in Saudi Colorectal Cancer.
Abdalla AN; Malki WH; Qattan A; Shahid I; Hossain MA; Ahmed M
Molecules; 2021 Jan; 26(2):. PubMed ID: 33440689
[TBL] [Abstract][Full Text] [Related]
59. Doenjang hexane fraction-induced G1 arrest is associated with the inhibition of pRB phosphorylation and induction of Cdk inhibitor p21 in human breast carcinoma MCF-7 cells.
Choi YH; Choi BT; Lee WH; Rhee SH; Park KY
Oncol Rep; 2001; 8(5):1091-6. PubMed ID: 11496322
[TBL] [Abstract][Full Text] [Related]
60. Cell cycle protein suppression and p21 induction in differentiating Caco-2 cells.
Evers BM; Ko TC; Li J; Thompson EA
Am J Physiol; 1996 Oct; 271(4 Pt 1):G722-7. PubMed ID: 8897894
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
